Key result
Intracoronary adenosine or SNP during primary PCI fails to reduce infarct size, while adenosine increases major cardiovascular events.
Why the study?
Microvascular obstruction following PPCI for STEMI contributes to infarct expansion, LV remodelling, and worse outcomes, prompting investigation into whether IC adenosine or SNP reduces infarct size or MVO.
Does intra-coronary high-dose adenosine or sodium nitroprusside reduce infarct size on CMR in STEMI patients undergoing primary PCI?
RCT (n=247)
Open-label
1:1:1
Yes
Does intra-coronary high-dose adenosine or sodium nitroprusside reduce infarct size on CMR in STEMI patients undergoing primary PCI?
Answers are grounded in this paper and cite their sources.
High-dose intra-coronary adenosine or sodium nitroprusside during primary PCI for STEMI does not reduce infarct size or microvascular obstruction, and adenosine may increase the risk of adverse clinical outcomes.
BACKGROUND: Microvascular obstruction (MVO) following primary percutaneous coronary intervention (PPCI) treatment of ST-segment elevation myocardial infarction (STEMI) contributes to infarct expansion, left ventricular (LV) remodelling, and worse clinical outcomes. The REFLO-STEMI trial tested whether intra-coronary (IC) high-dose adenosine or sodium nitroprusside (SNP) reduce infarct size and/or MVO determined by cardiac magnetic resonance (CMR). METHODS AND RESULTS: REFLO-STEMI, a prospective, open-label, multi-centre trial with blinded endpoints, randomized (1:1:1) 247 STEMI patients with single vessel disease presenting within 6 h of symptom onset to IC adenosine (2-3 mg total) or SNP (500 μg total) immediately following thrombectomy and again following stenting, or to standard PPCI. The primary endpoint was infarct size % LV mass (%LVM) on CMR undertaken 24-96 h after PPCI (n = 197). Clinical follow-up was to 6 months. There was no significant difference in infarct size (%LVM, median, interquartile range, IQR) between adenosine (10.1, 4.7-16.2), SNP (10.0, 4.2-15.8), and control (8.3, 1.9-14.0), P = 0.062 and P = 0.160, respectively, vs. CONTROL: MVO (% LVM, median, IQR) was similar across groups (1.0, 0.0-3.7, P = 0.205 and 0.6, 0.0-2.4, P = 0.244 for adenosine and SNP, respectively, vs. control 0.3, 0.0-2.8). On per-protocol analysis, infarct size (%LV mass, 12.0 vs. 8.3, P = 0.031), major adverse cardiac events (hazard ratio, HR, 5.39 [1.18-24.60], P = 0.04) at 30 days and 6 months (HR 6.53 [1.46-29.2], P = 0.01) were increased and ejection fraction reduced (42.5 ± 7.2% vs. 45.7 ± 8.0%, P = 0.027) in adenosine-treated patients compared with control. CONCLUSIONS: High-dose IC adenosine and SNP during PPCI did not reduce infarct size or MVO measured by CMR. Furthermore, adenosine may adversely affect mid-term clinical outcome. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01747174; https://clinicaltrials.gov/ct2/show/NCT01747174.
No takes yet. Share an insight, caveat, or question.
Nazir et al. (2016) conducted an RCT in ST-segment elevation myocardial infarction (STEMI) (n=247). Intra-coronary high-dose adenosine or sodium nitroprusside (SNP) vs. Standard PPCI was evaluated on Infarct size % LV mass (%LVM) on CMR undertaken 24-96 h after PPCI (p=0.062). Intra-coronary adenosine or SNP during primary PCI did not reduce infarct size vs control, while adenosine increased 6-month major cardiovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: